Oaktree Capital Management LP Takes $3.56 Million Position in Mesoblast Limited (NASDAQ:MESO)

Oaktree Capital Management LP bought a new position in shares of Mesoblast Limited (NASDAQ:MESO) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 179,593 shares of the company’s stock, valued at approximately $3,556,000. Oaktree Capital Management LP owned 0.14% of Mesoblast as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Strategic Financial Concepts LLC acquired a new position in shares of Mesoblast in the 4th quarter valued at $2,744,000. Jane Street Group LLC increased its stake in shares of Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares in the last quarter. Clayton Financial Group LLC acquired a new position in Mesoblast in the 4th quarter worth about $275,000. Ballentine Partners LLC acquired a new stake in Mesoblast in the fourth quarter valued at approximately $222,000. Finally, Lindbrook Capital LLC increased its position in shares of Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after buying an additional 901 shares in the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Price Performance

MESO opened at $12.11 on Friday. Mesoblast Limited has a twelve month low of $4.60 and a twelve month high of $22.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm’s 50-day moving average price is $16.31 and its 200 day moving average price is $13.16.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MESO. Piper Sandler reissued an “overweight” rating and issued a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Cantor Fitzgerald raised shares of Mesoblast to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.